Clinical and demOgRaphic Features of Patients With Uncontrolled Severe Asthma in Russia (CORSAR)

• ICS alone (duration, dosage);
• LABA alone (duration, dosage);
• ICS and LABA (duration, dosage);
• ICS and LABA plus:

a. Short-acting beta-agonists (SABA) (duration, dosage); b. LAMA (duration, dosage); c. LTRA (duration, dosage); d. Theophylline (duration, dosage); e. Macrolide antibiotics (duration, dosage).

Proportion of patients receiving OCS: intermittent/regularly; Median daily dose in case of regular OCS use; Median cumulative OCS exposure.

BMI ≥25 kg/m2

educational statuses: higher, secondary special, secondary general

• Proportion of patients with history of smoking/current smokers;
• Mean smoking index (pack-years) for current smokers;
• Proportion of patients with a history of alcohol abuse/current alcohol abuse;
• Proportion of patients with limitation of physical activity, related/non-related to asthma;
• Proportion of patients with overweight (BMI ≥25 kg/m2).

Proportion of patients with chronic rhinosinusitis with nasal polyps (CRSwNP), overall proportion and:

a. Proportions of patients with CRSwNP with different levels of eosinophils blood count: i. <150 cells/μl; ii. ≥150 cells/μl; iii. ≥300 cells/μl. b. Proportions of patients with CRSwNP with different levels of total IgE: i. ≤30 UI/ml; ii. >30 UI/ml; c. The proportion of patients with CRSwNP with a history of prior biologic treatment ('any biologic drugs used for asthma treatment in the past'); d. The proportion of patients with CRSwNP who were recommended to start biologic treatment at the first visit ('the need of biological therapy prescription').

cells/μl

• <150 cells/μl;
• ≥150 cells/μl;
• ≥300 cells/μl.

cells per high power field

IU/ml

• ≤30 UI/ml;
• >30 UI/ml;

parts per billion (ppb)

• Change of ICS;
• Dose of ICS increased;
• Addition of another drug for inhaled therapy

*Severe asthma exacerbation is defined as worsening of asthma requiring any of the following:

• use of systemic corticosteroids (CS) (or a temporary increase in a stable OCS background dose) for at least 3 days or a single depo-injectable dose of CS and/or
• an emergency room/urgent care visit (defined as evaluation and treatment for < 24 hours in an emergency department or urgent care center) due to asthma that required systemic CS (as per above) and/or
• an inpatient hospitalization (defined as admission to an inpatient facility and/or evaluation and treatment in a healthcare facility for ≥ 24 hours) due to asthma.

• Unscheduled outpatient visits;
• Emergency department visits/emergency calls;
• Hospitalizations.

• Mean pre- and post-bronchodilator forced expiratory volume in 1 second (pre- and post-FEV1);
• Mean pre- and post-bronchodilator forced vital capacity (pre- and post-FVC);
• Mean pre-bronchodilator forced expiratory flow (pre-FEF);
• Mean functional residual capacity (FRC), residual lung volume (RLV) and total lung capacity (TLC) evaluated by spirometry and/or body plethysmography.